In recent years, tungsten disulfide nanomaterials (WS₂NM) have had important applications in cancer therapy. Researchers have synthesized chitosan-functionalized WS₂ nanocomposites (CS/ WS₂/Ru) implanted with ruthenium nanoparticles. Chitosan is biocompatible and non-toxic, making it an excellent candidate for drug delivery systems. On the other hand, the biological properties of chitosan can be improved due to the small size and large surface area of WS₂.

Recently, WS₂NM-based nanocarriers have been developed in drug delivery systems, which also promote their application in tissue engineering. Due to the electrical properties of WS₂, researchers have designed tungsten disulfide nanomaterials (WS₂NM)-based electro-responsive drug delivery systems. Conventional drug delivery systems, such as oral and injectable, require higher concentrations of drugs to see therapeutic effects, and administering too much of the drug can lead to side effects in some patients.

Biocompatibility of tungsten disulfide nanomaterials (WS₂NM) such as tungsten disulfide inorganic nanotubes, and fullerene-like nanoparticles with salivary gland cells. There are currently no adequate methods to treat oral diseases due to impaired salivary gland function. The researchers investigated the biocompatibility of WS₂ in salivary gland cells. In the study, multi-walled inorganic nanotubes (INT- WS₂) and inorganic fullerene-like nanoparticles (IF WS₂) were synthesized in a reactor that can be used at high temperatures.

The high atomic number and near-infrared absorption of tungsten disulfide quantum dots (WS₂-QDs) (3 nm and 28 nm) of tungsten disulfide nanomaterials enable their synthesis as enhancers for X-ray computed tomography (CT)/photoacoustic imaging (PA), boosting their applications in bioimaging and radiotherapy.